19 completed, 9 recruiting, 2 not yet recruiting, 2 unknown. 35 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 35 | Completed 19, Recruiting 9, Not yet recruiting 2, Unknown 2, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 6 | Completed 3, Recruiting 2, Unknown 1 |
Follow Sweat Gland Diseases: new trials by email Literature Review of Sweat Gland Diseases trials Research Report on Sweat Gland Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS LOU064, Placebo - Hidradenitis Suppurativa | Phase 1 | Recruiting | Novartis Pharmaceuticals | 30 | 2026-10-15 | 2026-10-16 |
| Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa Soquelitinib - Hidradenitis Suppurativa (HS) | Phase 1 | Recruiting | Corvus Pharmaceuticals, Inc. | 25 | 2026-09-17 | 2026-10-15 |
| FEcal tranSplantation in HidradeniTIs suppuratiVA : a piLot Study Fecal microbiota transplantation (FMT) - Hidradenitis Suppurativa (HS), Fecal Microbiota Transplantation (FMT) | Phase 1 | Not yet recruiting | University Hospital, Clermont-Ferrand | 24 | 2026-06-01 | 2026-06-25 |
| SAR447971 First-in-human Study SAR447971, Placebo - Hidradenitis, Healthy Volunteers | Phase 1 | Recruiting | Sanofi | 122 | 2026-05-26 | 2026-10-27 |
| A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) Bimekizumab - Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis | Phase 1 | Recruiting | UCB Biopharma SRL | 20 | 2025-11-05 | 2026-09-18 |
| Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa Ruxolitinib Cream - Hidradenitis Suppurativa | Phase 1 | Recruiting | Incyte Corporation | 24 | 2025-11-03 | 2026-10-09 |
| 1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa) AviClear Lase Treatment, Sham (No Treatment) - Hidradenitis Suppurativa (HS) | Phase 1 | Recruiting | Wynn Medical Center | 30 | 2025-09-15 | 2025-09-17 |
| Neutralizing Interferon Type 1 in Hidradenitis Suppurativa Plasma with neutralizing autoantibodies to Type I Interferons - Hidradenitis Suppurativa (HS) | Phase 1 | Not yet recruiting | Centre Hospitalier Universitaire de Besancon | 6 | 2025-09-01 | 2025-07-16 |
| A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa LT-002-158 Tablets - Hidradenitis Suppurativa (HS) | Phase 1 / Phase 2 | Recruiting | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | 12 | 2025-07-08 | 2026-08-27 |
| A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients QLS12010, Placebo - Atopic Dermatitis, Hidradenitis Suppurativa (HS) | Phase 1 | Recruiting | Shanghai Qilu Pharmaceutical Research and Development Center LTD | 102 | 2025-03-31 | 2025-07-31 |
| Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients. HB0043 - Hidradenitis Suppurativa | Phase 1 / Phase 2 | Recruiting | Shanghai Huaota Biopharmaceutical Co., Ltd. | 15 | 2025-03-19 | 2026-01-07 |
| Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa SBT777101 - Hidradenitis Suppurativa | Phase 1 | Active not recruiting | Sonoma Biotherapeutics, Inc. | 24 | 2024-10-09 | 2026-02-20 |
| A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers LT-002-158/Placebo oral tablet(s) - Healthy Volunteer, Hidradenitis Suppurativa | Phase 1 | Completed | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | 150 | 2024-06-13 | 2026-08-27 |
| Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa Injectable suspension of allogeneic adult mesenchymal stem cells, Placebo - Hidradenitis Suppurativa | Phase 1 / Phase 2 | Unknown | Andalusian Network for Design and Translation of Advanced Therapies | 30 | 2022-10-26 | 2023-07-07 |
| A Clinical Study With Adalimumab Biosimilar Humira® (adalimumab) AC Pen [Reference Product], Adalimumab Richmond [Test Product] - Pharmacokinetics, Safety Issues | Phase 1 | Completed | Laboratorios Richmond S.A.C.I.F. | 150 | 2022-08-01 | 2024-03-04 |
| Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa AT193 - Hidradenitis Suppurativa | Phase 1 | Completed | Azora Therapeutics Australia Pty Ltd | 49 | 2021-11-23 | 2024-03-15 |
| A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa. RGRN-305, Placebo - Hidradenitis Suppurativa | Phase 1 | Completed | Aarhus University Hospital | 15 | 2021-09-01 | 2023-01-31 |
| Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) BDB-001 Injection, Placebo - Hidradenitis Suppurativa | Phase 1 / Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 50 | 2021-06-24 | 2024-03-26 |
| Allogeneic Micronized Amniotic Membrane Product for the Treatment of Hidradenitis Suppurativa AMP-001 Low Dose, AMP-001 Medium Dose, AMP-001 High Dose - Hidradenitis Suppurativa | Phase 1 | Withdrawn | IntegoGen, LLC | 2021-04-01 | 2021-09-08 | |
| LTX-109 as Treatment for Hidradenitis Suppurativa LTX-109 gel, 3% w/w - Hidradenitis Suppurativa | Phase 1 / Phase 2 | Completed | Pharma Holdings AS | 11 | 2021-03-05 | 2021-08-30 |
Showing 20 of 35. Sign in to see all of them.
Hidradenitis Suppurativa (24) · Hyperhidrosis (9) · Arthritis, Psoriatic (3) · Arthritis, Rheumatoid (3) · Dermatitis, Atopic (3) · Arthritis, Juvenile (2) · Colitis, Ulcerative (2) · Crohn Disease (2) · Hidradenitis (2) · Spondylitis, Ankylosing (2) · Autoimmune Diseases (1) · Axial Spondyloarthritis (1) · Depression (1) · Furunculosis (1) · Non-Radiographic Axial Spondyloarthritis (1)
Skin and Connective Tissue Diseases (35) · Skin Diseases (34) · Bacterial Infections (24) · Bacterial Infections and Mycoses (24) · Infections (24) · Skin Diseases, Bacterial (24) · Skin Diseases, Infectious (24) · Suppuration (24) · Hidradenitis (23) · Immune System Diseases (6) · Arthritis (4) · Joint Diseases (4) · Musculoskeletal Diseases (4) · Skin Diseases, Papulosquamous (4)
Botulinum Toxins, Type A (3) · 2-methylcyclopentadienyl manganese tricarbonyl (1) · Adalimumab (1) · Aluminum Chloride (1) · BDB001 (1) · Blood Cell Count (1) · Bone Morphogenetic Proteins (1) · Deodorants (1) · Ethanol (1) · Fecal Microbiota Transplantation (1) · Glycopyrrolate (1) · Granulocyte Colony-Stimulating Factor (1) · Hydroxychloroquine (1) · Sodium Chloride (1) · Vital Capacity (1)
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. (2) · University of Utah (2) · Aarhus University Hospital (1) · Andalusian Network for Design and Translation of Advanced Therapies (1) · Azora Therapeutics Australia Pty Ltd (1) · Botanix Pharmaceuticals (1) · CSL Behring (1) · Centre Hospitalier Universitaire de Besancon (1) · Chinese PLA General Hospital (1) · Corvus Pharmaceuticals, Inc. (1) · Dr. August Wolff GmbH & Co. KG Arzneimittel (1) · Elena Gonzalez Brant, MD (1) · Fresenius Kabi SwissBioSim GmbH (1) · GlaxoSmithKline (1) · Henry M. Jackson Foundation for the Advancement of Military Medicine (1)
United States (16) · China (6) · Germany (3) · Australia (2) · Denmark (2) · France (2) · Netherlands (2) · Spain (2) · Argentina (1) · Canada (1) · Norway (1) · South Korea (1) · Switzerland (1)
Colby Hansen, MD (2) · Ashwin Gollerkeri, MD (1) · Baoxi Wang, Master (1) · Bruce Strober, MD, PhD (1) · Elena M Gonzalez Brant, MD (1) · Ethel C. Feleder, MD (1) · Isin Sinem Bagci, MD (1) · Joseph Arron, MD PhD (1) · Paul F. Pasquina, M.D. (1) · Prof. Christoph Abels, MD, PhD (1)
PMID 31604104, PMID 35262901, PMID 37957373, PMID 38055242, PMID 40055981
2015 (1), 2018 (1), 2025 (1)